Dr. Nabil Saba, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Latin American University / School Of Medicine (unibe)

  Medical School, 1999

• Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy-A Meta-Analysis†, 2023-07-28

• Biomarkers predictive of response to pembrolizumab in head and neck cancer, 2022-12-07

• Signatures of somatic mutations and gene expression from p16INK4Apositive head and neck squamous cell carcinomas (HNSCC), 2020-09-28

• Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer, 2021-02-13

• Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer, 2022-05-10

• Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy, 2015-10-30

• A translational, pharmacodynamic and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer, 2015-02-11

• Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer, 2023-03-24

• Human Papillomavirus Oncoprotein E6 Upregulates c-Met through p53 Downregulation, 2016-07-22

• A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma, 2015-01-08

• A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer, 2022-05-26

• Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer, 2013-09-25

• Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study, 2013-10-03

• Associations among HPV, inflammation, and fatigue in head and neck cancer patients, 2018-05-09

• Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups, 2019-12-16

• Plasma metabolic phenotypes of HPV-associated vs smoking-associated head and neck cancer and patient survival, 2021-08-10

• A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma, 2018-02-13

• Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study, 2021-03-09

• Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?, 2015-12-07

• Impact of nivolumabvsstandard, single-agent therapy of investigator's choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141, a randomized, phase 3 trial, 2017-06-23

• Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy, 2017-01-11

• Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer, 2018-09-11

• Role of COX-2 in tumor progression and survival of head and neck squamous cell carcinoma, 2009-09-08

• Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors, 2012-12-24

• Electronic Cigarettes and Head and Neck Cancer Risk-Current State of Art, 2020-11-05

• Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer, 2023-04-19

• Phase 1B Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck, 2020-09-17

• Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck, 2021-07-15

• Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study), 2017-03-13

• Survival Outcomes by High-Risk HPV Status in Non-Oropharynx Head and Neck Squamous Cell Carcinomas: A Propensity-Scored Analysis of the National Cancer Data Base, 2019-04-23

• Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas, 2022-01-28

• Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma, 2022-06-01

• Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial, 2023-04-03

• Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance, 2019-09-13

• Heregulin and HER3 are Prognostic Biomarkers in Oropharyngeal Squamous Cell Carcinoma, 2015-07-20

• Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes, 2023-06-14

• Recurrent Differentiated Thyroid Cancer: The Current Treatment Options, 2023-05-10

• A network analysis of self-reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity-modulated radiotherapy, 2022-08-15

• Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck Cancers, 2020-09-06

• Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression, 2018-04-17

• Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016, 2021-07-20

• Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck, 2023-09-23

• The expanding role of IAP antagonists for the treatment of head and neck cancer, 2023-05-02

• Chromosome Translocations, Gene Fusions, and Their Molecular Consequences in Pleomorphic Salivary Gland Adenomas†, 2022-08-14

• The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma, 2016-11-14

• Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer, 2016-04-03

• Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer, 2021-12-14

• Radiomics in Hypopharyngeal Cancer Management: A State-of-the-Art Review†, 2023-03-06

• Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era, 2022-02-25

• Soy isoflavone supplementation increases long interspersed nucleotide element-1 (LINE-1) methylation in head and neck squamous cell carcinoma, 2019-03-12

• Trends, predictors and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005, 2015-10-06

• Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy, 2015-07-30